Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval

Suzhou Sanegene Bio Inc., an RNAi specialist with R&D centers in the U.S. and China, announced it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for its investigational C3-targeted siRNA drug SGB-9768 in complement-mediated hematological disorders. The approval enables clinical evaluation in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), expanding beyond its previously approved indications in complement-mediated kidney diseases.

Regulatory Expansion & Indication Portfolio

Drug Profile & Mechanism of Action

SGB-9768 represents a novel therapeutic approach targeting the central complement pathway:

• Mechanism: C3-targeted small interfering RNA (siRNA) that silences C3 protein production at the mRNA level
• Target Rationale: C3 serves as the central convergence point of all complement activation pathways, making it an ideal target for broad complement inhibition
• Administration: Subcutaneous delivery enabling convenient outpatient treatment
• Therapeutic Advantage: Addresses root cause of complement dysregulation rather than downstream effects

Phase I Clinical Data & Safety Profile

Completed Phase I trials demonstrated compelling proof-of-concept data:

• Efficacy: Single subcutaneous dose achieved dose-dependent, robust, and durable reductions in C3 levels
• Pathway Inhibition: Demonstrated sustained inhibition of complement pathway activity
• Safety: Favorable safety and tolerability profile with no significant adverse events
• Best-in-Class Potential: Duration and depth of C3 suppression position SGB-9768 as a potential best-in-class therapy

Market Opportunity & Unmet Need

• PNH Market: Global PNH therapeutics market valued at $3.5 billion annually, dominated by expensive monoclonal antibodies requiring frequent intravenous administration
• aHUS Burden: Ultra-rare disease with limited treatment options and high morbidity despite existing complement inhibitors
• Kidney Disease Expansion: IgAN alone affects 1.5-2 million patients globally, representing substantial commercial opportunity
• Competitive Differentiation: siRNA approach offers less frequent dosing and oral-like convenience compared to current IV/SC biologics

Strategic Implications for Sanegene Bio

• Platform Validation: Success across multiple complement-mediated diseases validates Sanegene’s RNAi platform capabilities
• Global Development Strategy: Dual U.S.-China R&D presence enables parallel regulatory pathways in major markets
• Portfolio Diversification: Expansion into both hematological and renal indications reduces single-indication risk
• Commercial Potential: Potential to capture significant share in high-value orphan disease markets with premium pricing

Competitive Landscape

• Current Standards: Monoclonal antibodies (eculizumab, ravulizumab) dominate complement inhibition but require bi-weekly or monthly IV/SC administration
• Differentiation Advantage: siRNA approach potentially enables quarterly or less frequent dosing with subcutaneous convenience
• Cost Structure: Manufacturing advantages of siRNA may enable competitive pricing while maintaining margins
• First-Mover Potential: Among first siRNA therapies targeting C3 in clinical development for these indications

Development Timeline & Next Steps

• Phase II Initiation: Expected to begin Q3-Q4 2026 in both hematological and renal indications
• Regulatory Strategy: Parallel development in China (NMPA) and U.S. (FDA) leveraging dual R&D infrastructure
• Partnership Potential: Strong clinical data may attract strategic partnership interest from global pharmaceutical companies
• Market Access: Orphan drug designations likely in both jurisdictions, providing market exclusivity and regulatory incentives

Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations for SGB-9768. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption patterns.-Fineline Info & Tech